Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 6/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26884633 | 1.00 | PIK3CB (0.35) | PIK3CBPIK3CACDK2KDM4EAPAF1 | |
| SCHEMBL27142746 | 0.85 | PIK3CA (0.40) | PIK3CBPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL27008304 | 0.85 | PIK3CA (0.40) | PIK3CBPIK3CAAKT1AKT2AKT3 | |
| SCHEMBL26884316 | 0.84 | PIK3CA (0.35) | PIK3CBPIK3CACDK2KDM4EAPAF1 | |
| SCHEMBL30742387 | 0.84 | PIK3CA (0.35) | PIK3CBPIK3CACDK2KDM4EAPAF1 | |
| SCHEMBL27134817 | 0.84 | PIK3CA (0.35) | PIK3CBPIK3CACDK2KDM4EAPAF1 | |
| SCHEMBL27008322 | 0.83 | PIK3CB (0.35) | PIK3CBPIK3CACDK2AKT1AKT2 | |
| SCHEMBL27132270 | 0.83 | PIK3CB (0.35) | PIK3CBPIK3CACDK2AKT1AKT2 | |
| SCHEMBL30741981 | 0.81 | CDK2 (0.40) | PIK3CBPIK3CACDK2 | |
| SCHEMBL30741979 | 0.81 | CDK2 (0.40) | PIK3CBPIK3CACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CB 16/4885PIK3CA 1/4885CDK2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.